Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, +1 more
Molecular Therapy (2017)
Hyaluronic-acid-functionalised polymeric nanoparticles delivered KPV to inflamed colonic tissue at a 12,000-fold lower effective concentration than the free tripeptide and accelerated mucosal healing in DSS colitis — proof-of-concept that the KPV translational problem may be delivery rather than activity.
This 2017 Molecular Therapy paper from the Merlin laboratory (the same group as Dalmasso 2008) attacks the central limitation of oral KPV as a therapeutic — the tripeptide is degraded rapidly in the gastrointestinal tract and the doses required to see the rodent-IBD effects observed in drinking-water studies are commercially impractical. The authors engineered hyaluronic-acid-functionalised polymeric nanoparticles loaded with KPV (HA-KPV-NPs, ~272 nm diameter) designed to bind CD44 receptors on inflamed colonic epithelium and macrophages. In a DSS-induced ulcerative-colitis model in FVB male mice, the HA-KPV-NPs achieved therapeutic efficacy — measured by colon-length preservation, body-weight recovery, histological inflammation scores, and pro-inflammatory cytokine expression — at a 12,000-fold lower KPV concentration than free tripeptide controls. Macrophage uptake of HA-functionalised nanoparticles was 74.7% by 12 hours, and TNF-α mRNA was significantly downregulated in HA-KPV-NP-treated macrophages versus untreated controls. The paper frames CD44-targeted nanoparticle delivery as the route by which the KPV pharmacology established in 2008 might reach humans at practical doses, and it set the template for a subsequent decade of similar delivery-engineering work in the IBD-peptide field.
This remains a rodent-pharmacology paper, not a human clinical trial. The 12,000-fold concentration improvement is a relative figure against free-KPV delivery in a comparison that already required high free-KPV doses to see effects — readers should understand it as a delivery-system improvement claim rather than an absolute pharmacological effect-size claim. The CD44 receptor targeting works in DSS colitis where epithelial CD44 expression is upregulated but human IBD lesion biology varies across disease subtypes and stages; CD44-targeted delivery has not been demonstrated in human ulcerative colitis. The nanoparticle preparation requires industrial-quality manufacturing and characterisation; translation to a commercially viable IBD drug product would require Phase 1 safety data on the nanoparticle vehicle as well as the peptide. The paper does not address chronic-dosing safety, repeated-cycle effects, or efficacy in inflammation already established at the chronic phase versus during acute induction. Industry interest in this delivery approach has grown but a randomized human trial of any KPV-nanoparticle product remains absent as of 2026.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.